Döhner, H., Schuh, A., Récher, C., O'Nions, J., Aldoss, I., Alfonso-Pierola, A., Allred, A., Alonso-Domínguez, J. M., Barreyro, L., Bories, P., Daskalakis, N., Porta, M. D., D'Souza, A., Dugan, J., Esteve, J., Fathi, A., Ferrante, L., Gaj, S., Garciaz, S., Garrido, A., Salamero, O., Guttke, C. D., Gyan, E., Hiebert, B., Jabbour, E., Jentzsch, M., Kantarjian, H., Konopleva, M., Krönke, J., Hütter-Krönke, M. L., Loefgren, C., Lomas, O., Mancini, V., Mantzaris, I., Morillo, D., Packman, K., Papayannidis, C., Philippar, U., Platzbecker, U., Paniagua, S. G., Sackey, N., Sauer, T., Searle, D. E., Shastri, P. N., Trancucci, D., Tovar, N., Vallet, N., Vaughan, L., Vyas, P., Wei, A., Röllig, C. (2025). Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations. Blood. https://doi.org/10.1182/blood-2025-5199